Comparison of different antisense oligonucleotides against the BCR/ABL junction in chronic myelogenous leukemia

  • Authors:
    • A Kaebisch
    • U Seay
    • S Wicker
    • C Weber
    • J Lohmeyer
    • J Ortigao
    • H Pralle
  • View Affiliations

  • Published online on: May 1, 1996     https://doi.org/10.3892/ijo.8.5.859
  • Pages: 859-864
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The activity of the BCR/ABL hybrid gene is associated with a growth advantage of the chronic myelogenous leukemia (CML) stem cell. Suppression of BCR/ABL hybrid gene expression can be a valuable tool for leukemic cell purging. Antisense oligonucleotides (ODNs) have the capacity to specifically downregulate gene expression. Data reported on the effect they have on BCR/ABL hybrid gene expression are controversial. We present data illustrating that prolongation of ODN half-life by means of chemical or sequence modification has only limited specific growth suppressive effect on BCR/ABL-positive clonogenic cells in vitro. Compared to unmodified phosphodiester ODNs (PO-ODNs) spanning the BCR/ABL junctions, modified ODNs with either a 3'-GC-clamp (GC-ODNs) or ODNs with one 3'-inverted nucleotide (3'-3' ODNs) to prevent 3'-exonuclease degradation, showed significantly prolonged extra- and intracellular half lives and different subcellular distributions in CML cell lines. In clonogenic assays from patients with CML, the modified ODNs were to some extent able to reduce colonies expressing BCR/ABL (GC-ODNs >3'-3'-ODNs >PO-ODNs). This difference did not become significant statistically. We demonstrate a substantially diminished hybridization efficacy of the modified antisense ODNs used, which may serve as a possible explanation for the failure to augment the leukemic cell purging efficacy.

Related Articles

Journal Cover

May 1996
Volume 8 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kaebisch A, Seay U, Wicker S, Weber C, Lohmeyer J, Ortigao J and Pralle H: Comparison of different antisense oligonucleotides against the BCR/ABL junction in chronic myelogenous leukemia. Int J Oncol 8: 859-864, 1996
APA
Kaebisch, A., Seay, U., Wicker, S., Weber, C., Lohmeyer, J., Ortigao, J., & Pralle, H. (1996). Comparison of different antisense oligonucleotides against the BCR/ABL junction in chronic myelogenous leukemia. International Journal of Oncology, 8, 859-864. https://doi.org/10.3892/ijo.8.5.859
MLA
Kaebisch, A., Seay, U., Wicker, S., Weber, C., Lohmeyer, J., Ortigao, J., Pralle, H."Comparison of different antisense oligonucleotides against the BCR/ABL junction in chronic myelogenous leukemia". International Journal of Oncology 8.5 (1996): 859-864.
Chicago
Kaebisch, A., Seay, U., Wicker, S., Weber, C., Lohmeyer, J., Ortigao, J., Pralle, H."Comparison of different antisense oligonucleotides against the BCR/ABL junction in chronic myelogenous leukemia". International Journal of Oncology 8, no. 5 (1996): 859-864. https://doi.org/10.3892/ijo.8.5.859